- E-postole-erik.iversen@uib.no
- BesøksadresseHaukeland universitetssykehus, Laboratoriebygget5009 Bergen
- PostadressePostboks 78045020 Bergen
Vitenskapelig artikkel
- (2022). Randomized implementation of a primary human papillomavirus testing-based cervical cancer screening protocol for women 34 to 69 years in Norway. Cancer Epidemiology, Biomarkers and Prevention. 1812-1822.
- (2019). Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecologic Oncology. 110-117.
- (2018). Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age. Human Vaccines & Immunotherapeutics. 396-403.
- (2018). Medikamentell abort hos avtalespesialist. Tidsskrift for Den norske legeforening. 823-828.
- (2018). Human papillomavirus type specific risk of progression and remission during long-term follow-up of equivocal and low-grade HPV-positive cervical smears. International Journal of Cancer. 851-860.
- (2017). Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy. Acta Obstetricia et Gynecologica Scandinavica. 547-555.
- (2017). Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - a combined analysis of five phase III clinical trials. Papillomavirus Research. The Journal of HPV and other Small DNA Tumor Viruses. 105-115.
- (2017). Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16?26 years: a randomised, double-blind trial. The Lancet. 2143-2159.
- (2017). 4-valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years. Pediatrics.
- (2016). Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials. Pediatrics.
- (2016). Implementing medical abortion with mifepristone and misoprostol in Norway 1998-2013. International Journal of Epidemiology.
- (2016). Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. Journal of the American Medical Association (JAMA). 2411-2421.
- (2016). Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. Papillomavirus Research. The Journal of HPV and other Small DNA Tumor Viruses. 61-69.
- (2015). Topical hexaminolevulinate photodynamic therapy for the treatment of persistent human papilloma virus infections and cervical intraepithelial neoplasia. Expert Opinion on Investigational Drugs. 273-281.
- (2015). Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Human Vaccines & Immunotherapeutics. 1313-1322.
- (2015). A randomized study of hexaminolevulinate photodynamic therapy in patients with cervical intraepithelial neoplasia 1/2. American Journal of Obstetrics and Gynecology. 465.e1-465.e7.
- (2015). A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine. 711-723.
- (2014). Recurrent high-grade cervical lesion after primary conization is associated with persistent human papillomavirus infection in Norway. Gynecologic Oncology. 159-166.
- (2014). Medical abortion with mifepristone and home administration of misoprostol up to 63 days' gestation. Acta Obstetricia et Gynecologica Scandinavica. 647-653.
- (2014). Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. e657-e665.
- (2014). Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiology, Biomarkers and Prevention. 1997-2008.
- (2012). Er det mulig å få pålitelig kunnskap om psykiske senvirkninger etter provosert abort? Tidsskrift for Den norske legeforening. 1450-1452.
- (2011). Decline of arterial cerebral infarction among young women: the Bergen Stroke Study. Vascular Health and Risk Management. 81-84.
- (2011). Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. International Journal of Cancer. 1344-1353.
- (2010). Oral Contraceptives and Venous Thromboembolism Consensus Opinion from an International Workshop held in Berlin, Germany in December 2009. Journal of family planning and reproductive health care. 117-122.
- (2010). Medical Abortion at 63 to 90 Days of Gestation. Obstetrics and Gynecology. 962-968.
- (2010). Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on all HPV-associated genital diseases in young women. Journal of the National Cancer Institute. 325-339.
- (2010). Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. British Medical Journal. 9 sider.
- (2009). Wrapping of the legs versus phenylephrine for reducing hypotension in parturients having epidural anaesthesia for caesarean section: a prospective, randomized and double-blind study. European Journal of Anaesthesiology. 842-846.
- (2009). The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. Journal of the European Academy of Dermatology and Venereology. 1147-1155.
- (2009). The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years. Journal of Infectious Diseases. 936-944.
- (2009). The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years. Journal of Infectious Diseases. 926-935.
- (2009). Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines. 696-704.
- (2009). Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. American Journal of Obstetrics and Gynecology. 603-607.
- (2009). A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prevention Research. 868-878.
- (2008). Pregnancy outcome in women before and after cervical conisation: population based cohort study. BMJ. British Medical Journal. 5 sider.
- (2008). Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. Journal of the National Cancer Institute. 475-482.
- (2008). HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 6844-6851.
- (2007). Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. Journal of Infectious Diseases. 1438-1446.
- (2007). Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 4931 -4939.
- (2007). Impact of recent studies on attitudes and use of hormone therapy among Scandinavian gynaecologists. Acta Obstetricia et Gynecologica Scandinavica. 1490-1495.
- (2007). Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. The Lancet. 1861-1868.
- (2006). NorChip saken - nok en gang. Gynekologen. 18-21.
- (2006). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer. 1459-1466.
- (2005). Molekylærdiagnostiske metoder innen gynekologisk kreft. Tidsskrift for Den norske legeforening. 3120-3123.
- (2005). Har conisering betydning for svangerskapsutfall? Gynekologen. 45-46.
- (2005). Ascitic complement system in ovarian cancer. British Journal of Cancer. 895-905.
- (2005). A significant change in Norwegian gynecologist´s attitude to hormone therapy is observed after the results of the Women´s Health Initiative Study. Acta Obstetricia et Gynecologica Scandinavica. 92-93.
- (2005). A significant change in Norwegian gynecologists attitude to hormone replacement therapy is observed after the results of the Women's health initiative study. Acta Obstetricia et Gynecologica Scandinavica. 92-93.
- (2004). Tredjegenerasjons p-piller - hvor stor er risikoen for venøs tromboemboli? Tidsskrift for Den norske legeforening. 1521-1522.
- (2004). Screening for serum total homocysteine in newborn children. Clinical Chemistry. 1769-1784.
- (2004). Practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric. 210-216.
- (2004). Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series. International Journal of Gynecological Cancer. 957-965.
- (2004). HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. The Lancet. 453-455.
- (2001). The development of high venous velocity of the fetal umbilical ring during gestational weeks 11–19. British Journal of Obstetrics and Gynaecology. 248-253.
- (2001). Mifepristone (RU 486) - et kontroversielt legemiddel med stort potensiale. Tidsskrift for Den norske legeforening. 3286-3289.
- (2001). Mifepriston - et kontroversielt legemiddel med stort potensiale. Tidsskrift for Den norske legeforening. 3658.
- (2001). Knowledge, attitudes and management strategies in Scandinavia concerning hormone replacement thereapy. A comparison between gynecologists in Denmark, Norway and Sweden. Maturitas. 83-90.
- (2001). Knowledge, attitudes and management strategies in Scandinavia concerning Hormone replacement therapy. Maturitas. 83-90.
- (2001). Gestagentillegg ved østrogenbehandling i klimakteriet. Tidsskrift for Den norske legeforening. 82-83.
- (2001). Early pregnancy termination with mifepristone and misiprostol in Norway. Acta Obstetricia et Gynecologica Scandinavica. 1056-1061.
- (2001). Beliefs about the use of oral contraception among women in Oslo, Norway. Scandinavian Journal of Sexology. 3-24.
- (2000). The effects of progestogens on the endometrium. Workshop (Sverige. Läkemedelsverket).
- (2000). Rehabilitering av kvinner med brystkreft. Tidsskrift for Den norske legeforening. 2749-2754.
- (2000). Methylation of hMLH1 in a population-based series of endometrial carcinoma. Clinical Cancer Research. 3607-3613.
- (2000). Loss of estrogen receptor (ER) expression in endometrial tumors is not associated with de novo methylation of the 5' end of the ER gene. Clinical Cancer Research. 4026-4032.
- (2000). Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Research. 1750-1752.
- (1999). Retained placenta: incidence and clinical significance. Acta Obstetricia et Gynecologica Scandinavica. 33-36.
- (1999). Prognostic significance of tumor angiogenesis, Ki-67, p53 and p21 expression - a population-based endometrial carcinoma study. Journal of Clinical Oncology. 1382-1390.
- (1999). Prognostic significance of angiogenesis, Ki-67, p53 and p21 expression - a population-based endometrial carcinoma study. International Journal of Oncology. 395-399.
- (1999). Consensus conference statement on combination oral contraceptives and cardiovascular disease. Fertility and Sterility. 1S-6S.
- (1998). Prognostic impact of morphometric nuclear grade of endometrial carcinoma. Cancer. 956-964.
- (1998). Prognostic impact of morphometric nuclear grade in endometrial carcinoma. Cancer. 956-964.
- (1998). Poorer survival of nulliparous women with endometrial carcinoma. Cancer. 1328-1333.
- (1998). Norske gynekologers holdning til østrogen substitusjon. Tidsskrift for Den norske legeforening. 2944-2946.
- (1998). Norske gynekologers holdning til og praksis ved hormonsubstitusjonsbehandling i klimakteriet. Tidsskrift for Den norske legeforening. 2940-2943.
- (1998). Independent prognostic importance of microvessel density in endometrial carcinoma. British Journal of Cancer. 1140-1144.
- (1998). Independent prognostic importance of microvessel density in endometrial carcinoma. British Journal of Cancer. 1140-1144.
- (1998). Identification of high-risk patients by assessment of nuclear Ki67 expression in a prosepective study of endometrial carcinoma patients. Clinical Cancer Research. 2779-2785.
- (1998). Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clinical Cancer Research. 2779-2785.
- (1998). Decreased survival for nulliparous women with endometrial carcinoma. Is the relationship due to biology or behaviour? Cancer. 1328-1333.
- (1998). Bør antiprogesteron tas i bruk ved svangerskapsavbrudd? Tidsskrift for Den norske legeforening. 12.
- (1998). Bør antiprogesteron tas i bruk i Norge? Tidsskrift for Den norske legeforening. 212-213.
- (1997). Vurdering av trombosetendens før forskrivning av p-piller. Tidsskrift for Den norske legeforening. 281-282.
- (1997). Tromboembolisk sykdom i graviditet og barseltid, underliggende trombofili? Gynekologen. 45.
- (1997). Svangerskapsavbrudd ved gruppe 1 sykehus i 1996. Tidsskrift for Den norske legeforening. 558.
- (1997). Recurrent endometrial carcinoma and the value of routine follow-up. British Journal of Obstetrics and Gynaecology. 1302-1307.
- (1997). Recurrence of endometrial carcinoma and the value of routine follow up. British Journal of Obstetrics and Gynaecology. 1302-1307.
- (1997). Prognostisk betydning av tumorbiologiske markører ved kreft i livmorslimhinnen. Kreftnytt. 4-7.
- (1997). Norske gynekologers innstilling til hormonell substitusjon. Gynekologen. 51-52.
- (1997). Cell division in placentas of appropriate and small-for-gestational-age infants. A flow cytometry study. Acta Obstetricia et Gynecologica Scandinavica. 59-62.
- (1997). Cell division in placentas of appropriate and small for gestational age infants. Acta Obstetricia et Gynecologica Scandinavica. 59-62.
- (1997). Cell division in placentas of appropriate and small for gestational age infants. Acta Obstetricia et Gynecologica Scandinavica. 59-62.
Vitenskapelig foredrag
- (2011). MEDICAL ABORTION WITH HOME ADMINISTRATION OF MISOPROSTOL UP TO 63 DAYS GESTATION.
- (2005). A burden of global proportions.
- (2004). Hvordan forholder vi oss i dag til brystkreftpasienter og risikokvinner mht østrogenbehandling?
- (2004). Human papilloma vaccines.
- (2004). Hormonbehandling etter brystkreft. Status i HABITS studien.
- (2004). HRT til kvinner med cancer.
- (2004). HABITS studien. Hvordan forholder vi oss i dag til brystkreftpasienter og risikokvinner mht østrogenbehandling?
- (2004). Corpuscancer.
- (2004). Changes in attitudes and use of hormone replacement therapy among Scandinavian Gynecologists.
- (2004). Breast issues with hormone therapy.
- (2003). Østrogenbehandling. Er det blitt farligere? Hvilke indikasjoner gjelder? Kontraindikasjoner?
- (2003). Østrogenbehandling for klimakterielt besvær - er det trygt etter brystkreft?
- (2003). Østrogenbehandling.
- (2003). a)HRT og CVD, b)HRT og cancer.
- (2003). Sikkerhetsaspekter, brystkreft og andre kreftformer, økning/reduksjon ved HRT.
- (2003). SMM rapport ovarialcancer og "HRT etter ca. mammae - er det trygt?".
- (2003). Postoperativ kjemoterapi ved ovarialcancer.
- (2003). P-piller-trombose.
- (2003). P-piller.
- (2003). Hjerte/karsykdom og østrogenbehandling.
- (2003). HRT og cancer.
- (2003). HRT og cancer.
- (2003). HRT og cancer.
- (2003). HRT og cancer.
- (2003). HRT og cancer.
- (2003). HRT og cancer.
- (2003). HRT og cancer.
- (2003). HRT etter cancer mammae - er det trygt?
- (2003). HRT etter HERS og WHI. Veien videre (Jordskjelv eller krusninger??).
- (2003). HRT eller WHI??
- (2003). HRT eller WHI??
- (2003). HRT and breast cancer. Hot topics in Gyn/Obst.
- (2003). HPV-vaksine. Kan cervixcancer forebygges?
- (2003). HPV-vaksinasjon. Bakgrunn og strategi.
- (2003). Global gene expression profiling of human cancers using DNA microarray technology - examples, pitfalls and outlook.
- (2003). Cx cancer: Fra naturlig forløp via terapi, sekundær -, til primærprofylakse.
- (2003). Corpuscancer.
- (2003). Bruk og misbruk av epidemiologiske data.
- (2003). Blødningsforstyrrelser.
- (2003). A change in attitudes and prescribing practice of hormone replacement therapy among Norwegian gynaecologists during the last 5 years.
- (2001). Substitusjonsbehandling i klimakteriet.
- (2001). Oppdatering prevensjon, p-piller og hormonelle metoder. Abortmetoder.
- (2001). Medisinsk abort - hvorfor og hvordan?
- (2001). HRT og coloncancer - er der en sammenheng?
- (2001). HRT og cancer mammae. HABITS-studien status 2001.
- (2001). HRT og cancer hos postmenopausale kvinner. En oppdatering.
- (2001). HRT cancer.
- (2001). HABITS-studien. Bakgrunn og status.
- (2001). HABITS-studien. Bakgrunn og status.
- (2001). HABITS-studien (Hormonal Replacement Therapy After Breast Cancer diagnosis - is it safe?). Bakgrunn og status.
- (2001). HABITS studien (Hormonal replacement therapy after breast cancer diagnosis - is it safe?) Bakgrunn og status.
- (2001). Corpuscancer.
- (2001). Bruk og misbruk av epidemiologiske data ved HRT og cancer mammae.
- (2001). Blødningsforstyrrelser i klimakteriet.
- (2000). Østrogenbehandling og kreftrisiko.
- (2000). The endometrium in postmenopausal asymptomatic women. Findings with transvaginal ultrasonography (TVS) and clinical relevance.
- (2000). Surgical evaluation following medically induced second trimester abortion. A Nordic Investigation.
- (2000). Surgical evacuation following medically induced second trimester abortion.
- (2000). Substitusjonsbehandling i klimakteriet.
- (2000). Medisinsk abort - hvorfor og hvordan?
- (2000). Hormonsubstitusjon og kreftrisiko.
- (2000). HTR og mammacancer, HABITS studien.
- (2000). HRT og brystcancer, relasjon til osteporose profylakse, fremtidige perspektiver.
- (2000). HRT i går, i dag og i morgen.
- (2000). HRT before, today and in the future.
- (2000). Gynekologiske cancere og HRT.
- (2000). Corpuscancer.
- (2000). Cancer mammae og HRT.
- (2000). Blødningsforstyrrelser i Klimakteriet.
- (1997). Use of the Janus serum bank in cancer research.
- (1997). Standardisert registrering av behandling av premaligne lidelser i cervix uteri, et prøveprosjekt i Helseregion III og IV.
- (1997). Peripartum hysterektomi - Insidens og maternell morbiditet.
- (1997). Peripartum hysterectomy. Incidence and maternal morbidity.
- (1997). Independent prognostic importance of microvessel density in endometrial carcinoma. [poster].
Populærvitenskapelig artikkel
- (2006). Utelukker tidligere brystkreft østrogenbehandling? Tidsskrift for Den norske legeforening. 611-612.
- (2004). Når redaktører krysser klinger. Tidsskrift for Den norske legeforening. 1830.
- (2003). Medikamentell abort ("abortpillen") - de første norske erfaringene. Tidsskrift for Den norske legeforening. 2422-2424.
- (2003). Hormonbehandling av kvinner med menopausale symptomer. Nye nasjonale anbefalinger. Nytt om legemidler forts. av: Nytt fra Statens legemiddelkontroll. 3-4.
- (2000). Økt bruk av p-pillen og hormonspiralen. Legemidler og samfunn.
- (2000). Progesteron - kilden til det gode liv? Dagen : kristelig dagblad.
- (2000). Professor vil gi abortpille til alle abortsøkende. Aftenposten (morgenutg. : trykt utg.). 2.
- (2000). Månedlige myter. Kvinner og Klær.
- (2000). Hvordan virker abortpillen. Dagen : kristelig dagblad.
- (2000). Feil om abortpillen. Aftenposten (morgenutg. : trykt utg.). 10.
- (2000). Angrepillen er ikke en tidlig abortpille. Stavanger Aftenblad.
- (1998). Prognostisk betydning av tumorbiologiske markører ved livmorkreft. Innsyn. 6-8.
- (1998). Prognostisk betydning av tumorbiologiske markører. Innsyn. Kontaktorgan fra Haukeland Sykehus.
- (1997). "Ubegrunnet p-pillefrykt". Legemidler og samfunn.
- (1997). "Er hormoner svaret på en problemfri alderdom?". Legemidler og samfunn. 20-21.
Kronikk
- (2021). Etablering av behandlingsmetoder uten kritisk refleksjon. Tidsskrift for Den norske legeforening. 1-6.
- (2018). Østrogener i menopausen - på tide å endre anbefalingene? Tidsskrift for Den norske legeforening. 532-534.
- (1999). Endometriecytologi - status 1999. Tidsskrift for Den norske legeforening. 2693.
- (1997). P-piller beskytter mot kreft. BA.
- (1997). Flere utførte aborter i 1996. Aftenposten (morgenutg. : trykt utg.).
- (1997). Angrepillen og aborter. Bergens Tidende.
- (1997). "Østrogen mot kreftplager". Dagbladet.
- (1997). "Østrogen er gunstig for kvinner. Økt brystkreftfare?". Stavanger Aftenblad.
- (1997). "Varmebehandling - jo før jo heller". BA.
Sammendrag/abstract
- (2012). Trender i bruken av medikamentell abort i Noreg. Gynekologen.
- (2012). Medical abortion with home administration of misoprostol up to 63 days gestation. Acta Obstetricia et Gynecologica Scandinavica. 33-34.
- (2012). Medical abortion at 9-12 weeks. Acta Obstetricia et Gynecologica Scandinavica. 49-49.
- (2012). Hexaminolevulinate photodynamic therapy for treatment of cervical dysplasia. Acta Obstetricia et Gynecologica Scandinavica. 148-148.
- (2012). HPV-vaksinasjon – er kunnskapsnivået hos norske medisinetstudenter og allmennleger tilstrekkelig høyt? Gynekologen. 43.
Vitenskapelig oversiktsartikkel/review
- (2020). Hormonbehandling i klimakteriet Hva er historien, og hvor står vi i dag? Gynekologen. 28-30.
- (2011). Masseundersøkelser mot gynekologisk kreft - status og fremtid. Tidsskrift for Den norske legeforening. 1550-1553.
- (2008). Strengthening prevention programs to eliminate cervical cancer in the Nordic countries. Acta Obstetricia et Gynecologica Scandinavica. 489-498.
- (2004). HPV test som supplement til cervixcytologi. Trenger vi det? Dagens medisin. 13.